Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Melanoma 1Carcinoma, Renal Cell 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 27Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × CB-839 × Thoracic × Clear all
NCT02771626 2023-03-17

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Calithera Biosciences, Inc

Phase 1/2 Terminated
118 enrolled 18 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04265534 2022-09-21

KEAPSAKE

Calithera Biosciences, Inc

Phase 2 Terminated
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡